TauRx Reports First Phase 3 Results for LMTX®

ABERDEEN, Scotland and SINGAPORE, July 27, 2016 /PRNewswire/ --

Promising Read-Out for First-Ever Tau Aggregation Inhibitor to Enter Phase 3 Trials  

• LMTX^® as monotherapy demonstrates significant reductions in disease progression in mild and moderate Alzheimer's disease 
• Strong results in both cognitive and functional tests supported by brain scan evidence of slow-down in progression of pathology 
• Study misses co-primary endpoints as LMTX^® as add-on therapy shows no beneficial effects
• Initial analysis from second phase 3 study in patients with mild Alzheimer's disease confirm positive findings 

TauRx Therapeutics Ltd today announced Phase 3 clinical trial results that show treatment with LMTX^®, the company's novel tau aggregation inhibitor, had a marked beneficial effect on key measures of Alzheimer's disease in patients with mild or moderate forms of the disease.

     (Logo: http://photos.prnewswire.com/prnh/20160727/393315LOGO )

While the TRx-237-015 study in 891 subjects failed to meet its co-primary endpoints, clinically meaningful and statistically significant reductions in the rate of disease progression were observed across three key measures in patients who were treated with LMTX^® as their only Alzheimer's disease medication. These three key measures comprised a cognitive assessment (ADAS-Cog), a functional assessment (ADCS-ADL) and an assessment of the level of brain atrophy (lateral ventricular volume, LVV, as measured by MRI). An abstract of the results will be presented during an open session at the 2016 Alzheimer's Association International Conference (AAIC) in Toronto, Canada this afternoon by Dr. Serge Gauthier, CM, MD, FRCPC, Director of the Alzheimer's Disease Research Unit, McGill University, Canada.

"In a study of this size across a combined mild to moderate patient population, it is both encouraging to see improvements of this magnitude in the standard cognitive and functional tests and reassuring to see the supporting brain scan evidence of a slowing in disease progression during 15 months of treatment," said Dr. Gauthier, "As a practising clinician I see Alzheimer's patients, their families and care-givers every day, and continually share their desperate need for a truly therapeutic product as today we only have symptomatic treatments available to us. In a field that has been plagued by consistent failures of novel drug candidates in late-stage clinical trials and where there has been no practical therapeutic advance for over a decade, I am excited about the promise of LMTX^® as a potential new treatment option for these patients."